

Application No. 10/814,025  
Amendment and Response to Restriction Requirement

### Amendment to the Claims

Claims 48-72 are pending in the application. Claim 60 is amended to correct the dependency. This listing of claims will replace all prior versions, and listing of claims in the application:

### Listing of Claims

1-47. (Cancelled)

48. (Previously Presented) A method for producing glucocerebrosidase useful for the treatment of a human patient having Gaucher's disease comprising the steps of:

- a. providing a culture of mammalian cells capable of expressing glucocerebrosidase;
- b. treating said cells with an inhibitor of carbohydrate processing that acts to inhibit the conversion of  $\text{Glc}_3\text{Man}_9\text{GlcNac}_2$  to smaller species; and
- c. recovering glucocerebrosidase from said culture, wherein said recovered glucocerebrosidase contains a higher number of exposed mannose residues than does human placental glucocerebrosidase.

49. (Previously Presented) The method of claim 48, wherein said inhibitor is deoxy-mannojirimycin.

50. (Previously Presented) The method of claim 48, wherein said inhibitor is swainsonine.

51. (Previously Presented) The method of claim 48, wherein said inhibitor is castanospermine.

52. (Previously Presented) The method of claim 48, wherein said inhibitor is deoxy-nojirimycin.

53. (Previously Presented) The method of claim 48, wherein said inhibitor is N-methyl-deoxy-nojirimycin.

54. (Previously Presented) A method of increasing the number of exposed mannose residues on glucocerebrosidase comprising treating a culture of mammalian cells expressing glucocerebrosidase with an inhibitor of carbohydrate processing that acts to inhibit the conversion of  $\text{Glc}_3\text{Man}_9\text{GlcNac}_2$  to smaller species.

Application No. 10/814,025

Amendment and Response to Restriction Requirement

55. (Previously Presented) The method of claim 54, wherein said inhibitor is deoxy-mannojirimycin.
56. (Previously Presented) The method of claim 54, wherein said inhibitor is swainsonine.
57. (Previously Presented) The method of claim 54, wherein said inhibitor is castanospermine.
58. (Previously Presented) The method of claim 54, wherein said inhibitor is deoxy-nojirimycin.
59. (Previously Presented) The method of claim 54, wherein said inhibitor is N-methyl-deoxy-nojirimycin.
60. (Currently Amended) A composition comprising glucocerebrosidase produced according to the method of claim 54 48.
61. A pharmaceutical composition useful for the treatment of a human patient having Gaucher's Disease comprising glucocerebrosidase containing a higher number of exposed mannose residues than human placental glucocerebrosidase, wherein said glucocerebrosidase is produced by treating cells expressing glucocerebrosidase with an inhibitor of carbohydrate processing that acts to inhibit the conversion of  $\text{Glc}_3\text{Man}_9\text{GlcNac}_2$  to smaller species.
62. (Previously Presented) The pharmaceutical composition of claim 61, wherein said inhibitor is deoxy-mannojirimycin.
63. (Previously Presented) The pharmaceutical composition of claim 61, wherein said inhibitor is swainsonine.
64. (Previously Presented) The pharmaceutical composition of claim 61, wherein said inhibitor is castanospermine.
65. (Previously Presented) The pharmaceutical composition of claim 61, wherein said inhibitor is deoxy-nojirimycin.
66. (Previously Presented) The pharmaceutical composition of claim 61, wherein said inhibitor is N-methyl-deoxy-nojirimycin.
67. (Previously Presented) A method of treating a human patient having Gaucher's disease comprising administering to said patient the composition of

Application No. 10/814,025

Amendment and Response to Restriction Requirement

claim 61 in an amount sufficient to alleviate the clinical symptoms of Gaucher's disease.

68. (Previously Presented) A method of treating a human patient having Gaucher's disease comprising administering to said patient the composition of claim 62 in an amount sufficient to alleviate the clinical symptoms of Gaucher's disease.
69. (Previously Presented) A method of treating a human patient having Gaucher's disease comprising administering to said patient the composition of claim 63 in an amount sufficient to alleviate the clinical symptoms of Gaucher's disease.
70. (Previously Presented) A method of treating a human patient having Gaucher's disease comprising administering to said patient the composition of claim 64 in an amount sufficient to alleviate the clinical symptoms of Gaucher's disease.
71. (Previously Presented) A method of treating a human patient having Gaucher's disease comprising administering to said patient the composition of claim 65 in an amount sufficient to alleviate the clinical symptoms of Gaucher's disease.
72. (Previously Presented) A method of treating a human patient having Gaucher's disease comprising administering to said patient the composition of claim 66 in an amount sufficient to alleviate the clinical symptoms of Gaucher's disease.